Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift ...

(NASDAQ:GH) announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to ...

Shockingly Simple 'Alert System' Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal ...

This follows the recent announcement of expanded Medicare coverage for Guardant Health's Reveal test, which is designed to detect colon cancer recurrence. Analysts from these firms anticipate that ...

I nvesting.com -- Shares of Guardant Health (NASDAQ:GH) have increased by 5.0% in premarket trading Tuesday following the company's announcement that its Guardant Reveal test for colon cancer has ...

a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients ...

demonstrating the utility of its Guardant Reveal™ test in rectal cancer treatment. The phase II NEO trial data, featured on January 25, 2025, shows that the liquid biopsy tool can aid in ...

jumped 12% in early trading Tuesday on news that Medicare coverage for its Guardant Reveal blood test has been expanded to include monitoring for disease recurrence in patients with colorectal ...

Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic or methylation analysis to detect circulating tumor DNA ctDNA , a marker of minimal ...